Samsung Biologics Co Ltd
KRX:207940
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
698 000
999 999.9999
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Samsung Biologics Co Ltd
Samsung Biologics Co Ltd
Selling, General & Administrative
Samsung Biologics Co Ltd
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Selling, General & Administrative
-₩655.5B
|
CAGR 3-Years
-68%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knotus Co Ltd
KOSDAQ:278650
|
Selling, General & Administrative
-₩33.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Selling, General & Administrative
-₩44.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Selling, General & Administrative
-₩7.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Selling, General & Administrative
-₩17.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-18%
|
|
|
C
|
Cellivery Therapeutics Inc
KOSDAQ:268600
|
Selling, General & Administrative
-₩11.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
Samsung Biologics Co Ltd
Glance View
Samsung Biologics Co., Ltd. is a prominent player in the biopharmaceutical industry, and its story reflects the growing importance of biologics in modern medicine. Founded in 2011 and headquartered in Incheon, South Korea, the company has quickly established itself as a leader in contract development and manufacturing services (CDMO) for biopharmaceuticals. With state-of-the-art facilities and a strong emphasis on quality and innovation, Samsung Biologics partners with global pharmaceutical companies to produce cutting-edge therapies, from monoclonal antibodies to recombinant proteins. The company's commitment to enhancing biotechnology capabilities is further highlighted by its substantial investments in expanding production capacity and capabilities, positioning it as a trusted partner in the fiercely competitive biomanufacturing landscape. For investors, Samsung Biologics represents a compelling opportunity in the rapidly growing biopharmaceutical sector, driven by increasing demand for effective therapies and the advancements in biologic drug development. The company has consistently demonstrated impressive financial performance, with significant revenue growth propelled by long-term contracts and collaborations with major biotech firms. Its strategic location in South Korea, coupled with a strong focus on regulatory compliance and sustainability, adds to its appeal as a stable and forward-thinking investment. As the global landscape continues to shift toward biologic treatments, Samsung Biologics is well-positioned to capitalize on this trend, making it an attractive prospect for those looking to invest in the future of healthcare innovation.
See Also
What is Samsung Biologics Co Ltd's Selling, General & Administrative?
Selling, General & Administrative
-655.5B
KRW
Based on the financial report for Jun 30, 2024, Samsung Biologics Co Ltd's Selling, General & Administrative amounts to -655.5B KRW.
What is Samsung Biologics Co Ltd's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-48%
Over the last year, the Selling, General & Administrative growth was -15%. The average annual Selling, General & Administrative growth rates for Samsung Biologics Co Ltd have been -68% over the past three years , -48% over the past five years .
You don't have any saved screeners yet
